Significant association for isoprostanes iPF2α-III, 2,3-dinor-iPF2α-III, and iPF2α-VI
FRIDAY, Dec. 2 (HealthDay News) -- Urinary F2-isoprostanes (iPF2α-III, 2,3-dinor-iPF2α-III, and iPF2α-VI) show a significant inverse association with the risk of type 2 diabetes, according to a study published online Nov. 18 in Diabetes Care.
Dora Il'yasova, Ph.D., from the Duke University Medical Center in Durham, N.C., and colleagues examined whether F2-isoprostane levels were inversely associated with type 2 diabetes risk, using the entire Insulin Resistance Atherosclerosis Study cohort. A total of 138 cases with incident type 2 diabetes and 714 non-case individuals were included. Liquid chromatography-tandem mass spectrometry was used to assay four F2-isoprostanes, including iPF2α-III, 2,3-dinor-iPF2α-III, iPF2α-VI, and 8,12-iso-iPF2α-VI, in baseline urine samples.
The investigators found that there was a significant inverse association seen between three F2-isoprostanes and type 2 diabetes risk, with adjusted odds ratios for iPF2α-III, 2,3-dinor-iPF2α-III, iPF2α-VI, and 8,12-iso-iPF2α-VI of 0.52 (95 percent confidence interval [CI], 0.39 to 0.67), 0.56 (95 percent CI, 0.42 to 0.73), 0.62 (95 percent CI, 0.48 to 0.79), and 0.91 (95 percent CI, 0.72 to 1.12), respectively.
"Our findings indicate that urinary F2-isoprostanes are inversely associated with type 2 diabetes risk beyond the traditional risk factors and may be useful in identifying high risk populations," the authors write.
Abstract
Full Text (subscription or payment may be required)